Robert M. Prins

James Madison University — United States

Immunology and Microbiology · Life Sciences

51h-index16.4kcitations482works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(181), Glioma Diagnosis and Treatment(133), Cancer Immunotherapy and Biomarkers(112), CAR-T cell therapy research(77), Immune cells in cancer(53)

Publications477 total

Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence
Cancer Cell·2025· 2 cited
Systems analysis uncovers early temozolomide responses and peptide antigens in glioblastoma
2025
IMMU-36. iHOTT: A Human Tumor–Immune Organoid Model for Interrogating Immunotherapy Response in Glioblastoma
Neuro-Oncology·2025Open Access
CTIM-12. DUAL IMMUNE CHECKPOINT BLOCKADE FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES
Neuro-Oncology·2025Open Access
CTIM-31. SAFETY AND TOLERABILITY OF OLAPARIB, TEMOZOLOMIDE, AND PEMBROLIZUMAB IN A PHASE 2 TRIAL IN PATIENTS WITH PROGRESSIVE GLIOBLASTOMA
Neuro-Oncology·2025Open Access
DDDR-12. Impact of clinical and molecular factors on pembrolizumab response in IDH-wildtype glioblastoma
Neuro-Oncology·2025Open Access
TMIC-88. MAPK- driven glioma progression and reprogramming of the tumor-associated immune response
Neuro-Oncology·2025
BIOM-83. INTEGRATED MONITORING OF RNA-SEQUENCING AND COMPLETE BLOOD COUNT PREDICTS IMMUNE RESPONSE AND OUTCOME IN A CLINICAL TRIAL OF DUAL NEOADJUVANT IMMUNE CHECKPOINT BLOCKADE IN GLIOBLASTOMA
Neuro-Oncology·2025Open Access
TMOD-35. Introducing MADR: A next-generation EGFR-driven glioblastoma model that recapitulates human immunotherapy resistance
Neuro-Oncology·2025Open Access
The activity of cold atmospheric plasma against high-grade glioma: a review
Journal of Neuro-Oncology·2025· 1 cited
P02.31.B INDUCTION OF A CHRONIC INTERFERON STIMULATED TUMOR-ASSOCIATED MYELOID CELL PHENOTYPE IS DIRECTLY ORCHESTRATED BY ABERRANT TUMOR-INTRINSIC EGFR-ACTIVATION IN GLIOBLASTOMA
Neuro-Oncology·2025Open Access
Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safety
Molecular Therapy·2025· 4 citedOpen Access
Immunotherapeutic targeting of NY-ESO-1 in malignant meningiomas with TCR-transduced T-cells
Journal of Neuro-Oncology·2025
Incomplete Cancer Surgery Correlates With Loss of Immune Surveillance and Hyper‐Progression of Disease
Journal of Surgical Oncology·2025Open Access
Cold atmospheric plasma effectively kills chordoma cells through induction of intracellular reactive oxygen species
Scientific Reports·2025· 1 citedOpen Access
A Human Tumor-Immune Organoid Model of Glioblastoma
2025· 1 citedOpen Access
Electric Vehicle Drive Cycle Simulation Constrained by Time and Current with Validation via Benchtop Testing
2025
Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure
Cell Reports Medicine·2025· 4 citedOpen Access
The T-cell receptor repertoire: A window into pediatric brain tumor immunity
Neuro-Oncology·2025· 1 cited
Advanced imaging characterization of post-chemoradiation glioblastoma stratified by diffusion MRI phenotypes known to predict favorable anti-VEGF response
Journal of Neuro-Oncology·2025Open Access
page 1 of 24Next →

Frequent Co-authors

Linda M. Liau(32), Timothy F. Cloughesy(19), William H. Yong(13), Horacio Soto(13), Richard G. Everson(8), Joey Orpilla(6), Paul S. Mischel(6), Albert Lai(6), Joseph Antonios(6), Benjamin M. Ellingson(5), Patrick Y. Wen(5), Sylvia K. Odesa(5), Aaron Mochizuki(4), Tom B. Davidson(4), Hideho Okada(4), David A. Nathanson(4), Thomas G. Graeber(4), Caius G. Radu(4), Noah Craft(4), Kevin W. Bruhn(4)